"Business Structure to Be Reshaped Around Three Core Pillars:
Cell and Gene Therapies, AI Healthcare, and Life Sciences"

CHA Bio Group has sold its entire stake in its affiliated venture capital firm, Solidus Investment, to JW Holdings.


On March 13, CHA Bio Group announced that CHA Biotech, along with its affiliates and related organizations, had transferred 100% of their shares in Solidus Investment to JW Holdings. The total sale price amounts to 30.6 billion won.


The shares sold consist of 46.5% from CHA Biotech, 29.6% from CHA Cares, 20.0% from CMG Pharmaceutical, and 3.9% from Sungkwang Medical Foundation. Through this transaction, the entire stake held by these entities will be transferred to JW Holdings. Solidus Investment is a venture capital firm focused on the bio and healthcare sectors.


Through this sale, CHA Bio Group plans to restructure its business portfolio by divesting investment assets and focusing on its core businesses. The secured funds will be used to strengthen its bio infrastructure, including research and development of cell and gene therapies (CGT), CDMO business, and investments in the digital healthcare sector.



Recently, CHA Bio Group has been pushing to reorganize its business structure around three core pillars: cell and gene therapies, AI healthcare, and life sciences. The group’s strategy is to dispose of investment assets with low relevance to its core business and concentrate resources on areas with potential for mid- to long-term growth.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing